Switch theme
Sign up to access all valuation multiples
InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.
2013
n/a
LTM Revenue $22.9M
LTM EBITDA -$43.1M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
InventisBio Co has a last 12-month revenue of $22.9M and a last 12-month EBITDA of -$43.1M.
In the most recent fiscal year, InventisBio Co achieved revenue of $25.6M and an EBITDA of -$36.7M.
InventisBio Co expects next 12-month revenue of XXX and NTM EBITDA of XXX
See InventisBio Co valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $25.6M | $20.6M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | 0% | XXX | XXX | XXX |
| EBITDA | -$36.7M | -$45.4M | XXX | XXX | XXX |
| EBITDA Margin | -143% | -221% | XXX | XXX | XXX |
| Net Profit | -$49.3M | -$66.6M | XXX | XXX | XXX |
| Net Margin | -193% | -324% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, InventisBio Co's stock price is CNY 21 (or $3).
InventisBio Co has current market cap of CNY 11.9B (or $1.6B), and EV of CNY 10.3B (or $1.4B).
See InventisBio Co trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.6B | XXX | XXX | XXX | XXX | $-0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, InventisBio Co has market cap of $1.6B and EV of $1.4B.
InventisBio Co's trades at 61.7x LTM EV/Revenue multiple, and -32.9x LTM EBITDA.
Analysts estimate InventisBio Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for InventisBio Co and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 68.8x | XXX | XXX | XXX |
| EV/EBITDA | -31.2x | XXX | XXX | XXX |
| P/E | -37.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpInventisBio Co's NTM/LTM revenue growth is 50%
InventisBio Co's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, InventisBio Co's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate InventisBio Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for InventisBio Co and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -20% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -221% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -171% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 23% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 239% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 270% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
InventisBio Co acquired XXX companies to date.
Last acquisition by InventisBio Co was XXXXXXXX, XXXXX XXXXX XXXXXX . InventisBio Co acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was InventisBio Co founded? | InventisBio Co was founded in 2013. |
| Where is InventisBio Co headquartered? | InventisBio Co is headquartered in China. |
| Is InventisBio Co publicy listed? | Yes, InventisBio Co is a public company listed on SHG. |
| What is the stock symbol of InventisBio Co? | InventisBio Co trades under 688382 ticker. |
| When did InventisBio Co go public? | InventisBio Co went public in 2022. |
| Who are competitors of InventisBio Co? | Similar companies to InventisBio Co include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of InventisBio Co? | InventisBio Co's current market cap is $1.6B |
| What is the current revenue of InventisBio Co? | InventisBio Co's last 12-month revenue is $22.9M. |
| What is the current EBITDA of InventisBio Co? | InventisBio Co's last 12-month EBITDA is -$43.1M. |
| What is the current EV/Revenue multiple of InventisBio Co? | Current revenue multiple of InventisBio Co is 61.7x. |
| What is the current EV/EBITDA multiple of InventisBio Co? | Current EBITDA multiple of InventisBio Co is -32.9x. |
| What is the current revenue growth of InventisBio Co? | InventisBio Co revenue growth between 2023 and 2024 was -20%. |
| Is InventisBio Co profitable? | Yes, InventisBio Co is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
